How AI will decrease overdiagnosis and overtreatment of prostate cancer
February 24 @ 12:00 pm - 1:30 pm EST
AI, short for artificial intelligence, is in the headlines increasingly. Medical care is expected to receive the biggest benefits in the field, including prostate cancer.
Please join Active Surveillance Patients International on Feb. 24 at noon-1:30 p.m. Eastern to hear a panel talk about AI and how it will be affecting our lives as prostate cancer patients in a program entitled “How AI will decrease over diagnosis and over treatment of prostate cancer.”
Our panel includes:
—Niels Olson, MD, is a board-certified pathologist and the Chief Medical Officer at the Defense Innovation Unit in Mountain View, California. In this role, he oversees research programs in machine learning/AI for a broad spectrum of anatomic pathology applications, augmented reality microscopy, and artificial intelligence applications in radiology.
—Daniel Spratt, MD, Chair of radiation oncology at University Hospitals in Cleveland, who ordered Artera for Bruno. He says two-thirds of men making the transition to radiation can now avoid ADT and its serious side effects.
—Tim Showalter, MD, MPH, is Chief Medical Officer at ArteraAI. He is a radiation oncologist and cancer researcher and a clinical professor at the University of Virginia. The Centers for Medicare and Medicaid Services recently set reimbursement rates for Artera AI.
—Bruno Barrey, a robotics engineer from suburban Detroit, who was able to avoid Androgen Deprivation Therapy because of an analysis by Artera AI as he transitioned from Active Surveillance to radiation treatment.
——Kirk Wojno, MD, a board-certified anatomic and clinical pathologist who trained at The Johns Hopkins, is Chief Medical Officer of Immunis.AI in the Detroit area. The company is using AI to develop a test to help newly diagnosed patients decide whether to go on active surveillance or active treatment.